The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter randomized phase II study of short course FOLFOX + nivolumab (Nivo) followed by maintenance Nivo +/- radiation (RT) in the first line treatment of metastatic or unresectable gastroesophageal adenocarcinoma (mGEA).
 
Manish A. Shah
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Oncolys BioPharma (Inst)
 
Sarbajit Mukherjee
Research Funding - Ipsen (Inst)
Other Relationship - Esophageal Cancer Action Network (ECAN)
 
Kelsey Klute
Consulting or Advisory Role - Agenus; Cancer Expert Now; Daiichi Sankyo/Lilly; Oncolytics; Pfizer
Research Funding - AIM ImmunoTech (Inst); AstraZeneca (Inst); FibroGen (Inst); RenovoRx (Inst)
 
Debra D'Angelo
No Relationships to Disclose
 
Sahrish Khan
No Relationships to Disclose
 
Nicholas J. Sanfilippo
No Relationships to Disclose
 
Paul J. Christos
No Relationships to Disclose
 
Jessica M. Frakes
No Relationships to Disclose
 
Jessica Delaney
No Relationships to Disclose
 
Sarah Chatley
No Relationships to Disclose
 
Kian-Huat Lim
Honoraria - CURIS
Patents, Royalties, Other Intellectual Property - Hold patent for targeting MK2 as a therapeutic strategy in pancreatic cancer.
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Strata Oncology (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Tizona Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)
 
Rutika Metha
Consulting or Advisory Role - Astellas Pharma; BostonGene; Bristol-Myers Squibb; GlaxoSmithKline; Guardant Health; Lilly; Merck; Natera; Novartis; Seagen
Research Funding - NCCN/Lilly